PURPOSE: To identify the prognostic factors for successful laser iridotomy for acute angle-closure glaucoma (AACG). METHODS: We retrospectively reviewed the medical records of 77 eyes of 77 patients with AACG with initial intraocular pressure (IOP) above 40 mmHg. All of the patients received maximum tolerable medical therapy (MTMT) followed by laser iridotomy. In order to comparatively analyze the factors affecting successful laser iridotomy, an increase in IOP on follow-up was defined as increase in IOP greater than 21 mmHg requiring medical or surgical treatment. RESULTS: Successful laser iridotomy was achieved in 59.7% (46/77 eyes). Thirty-one eyes (40.3%) exhibited increased IOP on follow-up, and of these, 30 eyes developed an increase in IOP within six months after the first attack. The success rate was higher (92.9%) in 42 patients who had greater than 30% IOP reduction by MTMT at the first attack compared to the 35 patients whose IOP reduction was less than 30%, of which 24 eyes (72.7%) showed more than 30% IOP reduction after intravenous hyperosmotic agent treatment (p=0.012). The success rate was higher in patients treated within seven days after the development of symptoms than in those treated after seven days (Odds ratio, 4.51; 95% confidence interval, 1.38 to 14.75). CONCLUSIONS: Our data suggest that we can expect successful IOP control after laser iridotomy in eyes with AACG if the patient can be treated within seven days after the development of symptoms and if the IOP reduction was more than 30% by MTMT.
Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Female ; Filtering Surgery/*methods ; Follow-Up Studies ; Glaucoma, Angle-Closure/physiopathology/*surgery ; Humans ; Intraocular Pressure/physiology ; Iris/*surgery ; Laser Therapy/*methods ; Male ; Middle Aged ; Prognosis ; Retrospective Studies

A total of 56 subjects with multiple nematode infections with T. trichiura, Ascaris, hookworms and Enterobius were treated with oxantel and pyrantel pamoate mixture in a paratable suspension(50 mg of each per ml). A single dose of 10 mg per kg body weight in each cured 100 per cent of 54 subjects with Ascaris, 97.1 per cent of 35 subjects with hookworms, 77.8 per cent of 36 with Enterobius and 73.2 per cent of 56 subjects with T. trichiura infestation. The mean egg per gram stool reduction rate in T. trichiura infection was 91.9%. Of the 31 subjects infected with Ancylostoma doudenale 96.8% were cured with a single dose and 4 infected with Necator americanus showed a 100% cure rate with a similar daily dose on 3 consecutive days. Side effects were few and mild. There was no clinical or laboratory evidence of drug toxicity. These findings show a single dose of oxantel and pyrantel pamoate mixture to be a highly effective and acceptable treatment for multiple infections with these nematodes.
parasitology-helminth-nematoda ; Trichuris trichiura ; Ascaris lumbricoides ; hookworm ; Enterobius vermicularis ; chemotherapy-oxantel pamoate-pyrantel pamoate

PURPOSE: The purpose of this study was to evaluate the high-resolution CT features of Swyer-James syndrome with special attention to the airway lesions and to determine the clinical utility of high-resolution CT compared with that of chest radiography. MATERIALS AND METHODS: In seven patients with Swyer-James syndrome, we retrospectively reviewed chest radiographs obtained during inspiration and expiration and high-resolution CT scans obtained in inspiration. The high-resolution CT appearance was evaluated and compared with that of chest radiography. RESULTS: On both chest radiographs and high-resolution CT, the affected lung volume was relatively diminished in four patients and normal in three patients. In all seven patients, chest readiographs showed hyperlucency of the lung which was unilateral in four and bilateral in three patients. Unilateral small hilum was seen in six patients and bronchiectasis was demonstrated in one patient on chest radiographs. The hyperlucent lung volume was not diminished on expiratory radiographs in all seven patients. In all patients, high-resolution CT demonstrated low attenuation regions of the lung either bilaterally(n=5) or unilaterally(n=2). Pulmonary vessels were markedly decreased in size and number in the lung parenchyma with low attenuation. Six patients had bronchiectasis on high-resolution CT, which were cylindrical or varicose in five and cystic in one. Bronchiolectasis was observed in three patients on high-resolution CT. CONCLUSION: The high-resolution CT findings are characteristic of Swyer-James syndrome. High-resolution CT is more sensitive than chest radiography in detecting regions of low attenuation and bronchiectasis and may be useful for the diagnosis of Swyer-James syndrome. Our results suggest that bronchiectasis is a frequently associated airway lesion of Swyer-James syndrome and bronchiolectasis may be associated in some cases.
Bronchiectasis ; Diagnosis ; Humans ; Lung ; Lung, Hyperlucent* ; Radiography ; Radiography, Thoracic ; Retrospective Studies ; Thorax ; Tomography, X-Ray Computed

No abstract available.
Herniorrhaphy* ; Polyethylene Terephthalates*

No abstract available.
Sepsis* ; Yersinia*

No abstract available.

PURPOSE: We assessed changes of the choroidal thickness in healthy Korean children using enhanced depth imaging (EDI) optical coherence tomography (OCT) and evaluated the association of choroidal thickness and axial length. METHODS: Seventy-nine eyes (79 children) within +/-1 diopter spherical equivalent underwent horizontal and vertical scan using EDI OCT. Two observers determined independently the choroidal thickness at 1 mm intervals from 3 mm nasal and 4 mm temporal to the fovea and 1 mm superior and inferior to the fovea using the manual caliper provided by the device software. Statistical analysis was performed to evaluate variations of choroidal thickness at each location and to correlate choroidal thickness and axial length. Intraclass correlation coefficient (ICC) was calculated. RESULTS: The subjects' mean age was 7.67 years. The mean axial length was 22.96 mm and mean subfoveal choroidal thickness was 296.13 microm. The thinnest choroidal thickness was 160.57 microm at 3 mm nasal to the fovea and the thickest was 319.49 microm at 4 mm temporal to the fovea. The choroidal thickness at 1 mm superior (294.70 microm) and inferior (287.11 microm) to the fovea showed no statistical significance compared with the subfoveal choroidal thickness. The mean choroidal thickness was thicker at 3 mm and 2 mm nasal to the fovea in eyes with shorter than the mean axial length (p < 0.05). For the assessment of intra-observer reproducibility, the ICC ranged from 0.995 to 0.998 (p < 0.001). CONCLUSIONS: The choroidal thickness increased from the nasal to the temporal direction at the posterior pole and eyes with shorter axial lengths tended to present thicker choroids at the nasal area in healthy Korean children.
Child* ; Choroid* ; Humans ; Tomography, Optical Coherence*

PURPOSE: To compare central macular thickness (CMT) and visual acuity outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of diabetic macular edema (DME). METHODS: Fifty-one patients were randomly choosen to receive an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed, and 28 of 51 received an intravitreal injection of triamcinolone acetonide while the remaining 23 received bevacizumab injection. All patients underwent Snellen visual acuity testing, optical coherence tomography imaging and ophthalmoscopic examination at baseline and at four weeks following the injection. RESULTS: In the triamcinolone group, CMT decreased from 656.71+/-194.37 micrometer at baseline to 312.46+/-102.14 micrometer at the four-week follow-up visit, while in the bevacizumab group, CMT decreased from 582.17+/-151.02 micrometer at baseline to 453.09+/-172.39 micrometer at the follow-up (p<0.05). The LogMAR best-corrected visual acuity converted from the Snellen visual acuity significantly improved in the triamcinolone group (from 0.89+/-0.38 to 0.67+/-0.33) compared to the bevacizumab group (from 0.79+/-0.31 to 0.70+/-0.34) [p<0.05]. CONCLUSIONS: Intravitreal injection of triamcinolone may offer advantages over bevacizumab in the short-term management of DME, specifically with respect to improvement in CMT and visual acuity.
Antibodies, Monoclonal, Humanized ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Macular Edema ; Retrospective Studies ; Tomography, Optical Coherence ; Triamcinolone ; Triamcinolone Acetonide ; Visual Acuity ; Bevacizumab

PURPOSE: To compare central macular thickness (CMT) and visual acuity outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of diabetic macular edema (DME). METHODS: Fifty-one patients were randomly choosen to receive an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed, and 28 of 51 received an intravitreal injection of triamcinolone acetonide while the remaining 23 received bevacizumab injection. All patients underwent Snellen visual acuity testing, optical coherence tomography imaging and ophthalmoscopic examination at baseline and at four weeks following the injection. RESULTS: In the triamcinolone group, CMT decreased from 656.71+/-194.37 micrometer at baseline to 312.46+/-102.14 micrometer at the four-week follow-up visit, while in the bevacizumab group, CMT decreased from 582.17+/-151.02 micrometer at baseline to 453.09+/-172.39 micrometer at the follow-up (p<0.05). The LogMAR best-corrected visual acuity converted from the Snellen visual acuity significantly improved in the triamcinolone group (from 0.89+/-0.38 to 0.67+/-0.33) compared to the bevacizumab group (from 0.79+/-0.31 to 0.70+/-0.34) [p<0.05]. CONCLUSIONS: Intravitreal injection of triamcinolone may offer advantages over bevacizumab in the short-term management of DME, specifically with respect to improvement in CMT and visual acuity.
Antibodies, Monoclonal, Humanized ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Macular Edema ; Retrospective Studies ; Tomography, Optical Coherence ; Triamcinolone ; Triamcinolone Acetonide ; Visual Acuity ; Bevacizumab

No abstract available.
Bronchiectasis* ; Bronchography*